RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Operating income

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Period EndOperating income (Million USD)YoY (%)
Dec 31, 2024-233-106.08%
Dec 31, 20233,832-11.04%
Dec 31, 20224,307+54.83%
Dec 31, 20212,782-2.60%
Dec 31, 20202,856+138.51%
Dec 31, 20191,198+88.55%
Dec 31, 2018635+415.36%
Dec 31, 2017123+1140.37%
Dec 31, 201610-102.13%
Dec 31, 2015-467-32.57%
Dec 31, 2014-692-23.36%
Dec 31, 2013-903-38841.34%
Dec 31, 20122-97.95%
Dec 31, 2011114-116.35%
Dec 31, 2010-696

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)